High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers

Leonel Varela Cagetti (1) , Christophe Zemmour (2, 3) , Naji Salem (1) , Mathieu Minsat (4) , Marjorie Ferré (5) , Hughes Mailleux (1) , Marc Giovaninni (1) , Bernard Lelong (1) , Cécile de Chaisemartin (1) , Pauline Ries (1) , Flora Poizat (1) , Agnès Tallet (1) , Laurence Moureau-Zabotto (1)

1 IPC - Institut Paoli-Calmettes
2 CRCM - Centre de Recherche en Cancérologie de Marseille
3 SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD - Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale
4 Institut Curie [Paris]
5 Département de Radiothérapie [IP-C, Marseille]

The purpose of this study was to analyze and compare clinical outcomes of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy boost (ISBT) after EBRT or radio chemotherapy for the treatment of anal canal cancers.

Mots clés: Anal cancer; Boost; Brachytherapy; Chemoradiation; Colostomy-free survival

Domaines: Sciences du Vivant [q-bio]; Biologie cellulaire

Leonel Varela Cagetti, Christophe Zemmour, Naji Salem, Mathieu Minsat, Marjorie Ferré, et al.. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers. Brachytherapy, 2019, 18 (6), pp.814-822. ⟨10.1016/j.brachy.2019.08.005⟩. ⟨hal-02533391⟩